• Cyclops Nickel-Cobalt project license fully compliant under updated mining registration process
• National, provincial and local support received for project
• Strategic partner and investor discussions have commenced
• Indonesia is currently the largest nickel producer worldwide

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE), an Indonesia-based company focused on developing nickel-cobalt opportunities in the Asia-Pacific region, received the approval of the Republic of Indonesia Ombudsman for the registration of the Cyclops Nickel-Cobalt Project license. The project license will be transferred into a foreign investment license, where it will be administered by the central government, according to a company announcement (http://ibn.fm/5v51V).

The Cyclops Project, located in Papua Province, Indonesia, is mining and environmentally permitted with year-round access. In 2019, the company carried out a large-scale exploration and development program at its flagship 5000-hectare, Cyclops Nickel-Cobalt project. Drilling identified significant horizons of nickel mineralization and bench-scale scoping tests yielded positive results for processing of this nickel rich material.

“2019 was a pivotal year for us, and we’re pleased to carry this momentum into 2020. Obtaining approval from Indonesia’s Ombudsman is an important step toward our goal of securing strategic partnerships and participating in Asia’s growing battery metals supply chain,” Ranjeet Sundher, CEO of Pacific Rim Cobalt, stated in a news release.

Pacific Rim Cobalt Corp. is focused on the development of nickel-cobalt projects ideally located close to China, the world’s first and largest “Gigafactory.” Nickel and cobalt are critical components of lithium-ion batteries and are currently in a global supply deficit. Indonesia is currently the largest nickel producer on earth with a mandate to become a global superpower in the international electric vehicle and battery metals supply chain.

The year 2020 will see continued and consistent development in Pacific Rim Cobalt’s strategy as the company continues to set ambitious milestones with the goal of becoming a leading international player in the EV battery metal sector and creating significant long-term shareholder value. This includes preparations to commission and operate the company’s pilot plant in Canada, which will contain an integrated circuit to produce high-purity nickel and cobalt strip solutions to develop battery-grade nickel and cobalt.

For more information, visit the company’s website at www.PacificRimCobalt.com

NOTE TO INVESTORS: The latest news and updates relating to PCRCF are available in the company’s newsroom at http://ibn.fm/PCRCF

• SING’s current strategy includes focused marketing, sales-development initiatives
• Company “strongly committed” to continued development, improvement of Direct Solar America subsidiary
• SEIA dubs 2020s the solar+ decade; SING set to capitalize on solar becoming leading source of new-energy generation

Following a week during which its subsidiary Direct Solar America reported increased growth in terms of new contract development, SinglePoint Inc. (OTCQB: SING) notes that the company’s 2020 strategy – which includes new marketing and sales development initiatives – is starting to take shape (http://ibn.fm/FRG97). Designed primarily around Direct Solar America, those initiatives are comprised of starting new canvassing teams, improving customer service and increasing engagement of partnership channels.

“We are strongly committed to continuing the development and improvement of Direct Solar America,” SinglePoint CEO Greg Lambrecht stated in a news release. “The company’s model continues to impress us by the ability to scale with few constraints into new markets. As we continue to see states rolling out incentives, we are able to act quickly and assess the market viability in order to decide whether to roll out teams in that area. Solar continues to be a driving factor and hot topic in the media, which I believe has resulted in the company expanding as rapidly as [it] has. Direct Solar America, as a standalone entity, eclipsed $2 million in revenue in just six months of business.”

SING’s deliberate focus appears well founded as the Solar Energy Industries Association (SEIA) reports that the U.S. solar market surpassed 2 million installations in Q1 2019 (http://ibn.fm/JlwGP). The association anticipates the industry will hit 3 million installations in 2021 and 4 million installations in 2023, growth that comes as an increasing number of consumers look to address environment concerns and take advantage of reduced installation costs.

The 2020s have been called the solar+ decade by the SEIA. “The 2010s were filled with more highs than lows, and the solar industry is in a strong position to become the leading source of new-energy generation this decade,” added SEIA president and CEO Abigial Ross Hoppe. “Working in collaboration with other clean-energy technologies, including storage, solar will lead a clean-energy economic boom while also reducing greenhouse gas emissions.”

That anticipated growth was also the focus of a recent podcast by SinglePoint CFO Corey A. Lambrecht (http://ibn.fm/JMy1B). “What we are looking for as we get into a full year’s worth of growth is to really accelerate those revenues on the residential side and use that as our foundation going forward into 2020 and beyond,” Lambrecht continued. “And then hopefully as we’ve focused on some commercial opportunities as well, we can add those in. We had nice revenue growth throughout 2019. We learned a lot, absorbed the startup costs, and it was successful.”

The newest member of the SING leadership team, Lambrecht explained that “what intrigued me about Direct Solar is their unique business model. And the business model around them is to really become the solar expert for homeowners and to help installers get qualified candidates out there that are looking to put solar on residential. They do it by the way of an asset-like model, which is very similar to what we built in the landfill diversion space. We didn’t have any trucks or services, and we didn’t own any of the landfills, so basically we were aligned with the material, making sure it had its highest and best use going forward.”

Lambrecht brings with him more than 20 years of experience as a public-company executive with broad experience in strategic acquisitions, corporate turnarounds, new business development, pioneering consumer products, corporate licensing, and interactive technology services. “I think one of the things for the shareholders of SinglePoint to make note of is that I have been involved with a national scale roll-up like this in the past,” Lambrecht added. “There are going to be some bumps along the way, but there are going to be tailwinds driving this particular industry for solar over the next number of years.”

SinglePoint provides investors with the opportunity to make investments across a wide range of assets that currently include but are not limited to solar energy, hemp, mobile-payment applications and more. SING is leveraging technology expertise into emerging opportunities. By building a portfolio in undervalued companies the company is able to provide a rich, diversified holding base and create branded products.

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• More than 40 years of next level experience with mulch manufacturing, colorant production, product innovation and treating/caring for trees and tree debris recycling.
• Services include tree removal, trimming, grapple hauling, land clearing, stump grinding, mulch processing, colorant production and packaging, transportation and distribution.
• Acquisition of Mulch Manufacturing provides NSRI a significantly larger footprint nationally and abroad.
• Mulch Manufacturing maintains its historical contracts with big box retailers nationally for bagged mulch sales.
• NSRI benefits from a competitive advantage over other mulch manufacturers because the acquisition of mulch feedstock drives revenue instead of simply being a cost of goods sold.
• Environmentally responsible corporation focused on being “stewards of the environment” in all aspects of the business. The source of feedstock coming from tree services division decreases environmental burden on landfills.
• Ample room for expansion utilizing the 100-acre site in Florida approved as the flagship tree debris collection site and mulch feedstock production facility, as well as the 100,000-sq.-ft. building and 28 acres site in Jacksonville.
• Recipient of Angie’s List Super Service Award in 2018
• Strategic partnership with a national waste disposal company has provided NSRI millions of dollars in cost savings and years of time that would otherwise have been incurred if the Company had needed to secure the required locations and permits that the partnership provided. This partnership represents significant potential expansion opportunity for NSRI.

National Storm Recovery Inc. (OTC: NSRI), through its subsidiaries, including National Storm Recovery, LLC (DBA Central Florida Arbor Care and Mulch Manufacturing, Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

National Storm and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

National Storm’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

National Storm in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing, Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides National Storm with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

National Storm’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

National Storm plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as the company’s flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow National Storm’s debris hauling division to realize significant savings on its transportation costs.

National Storm has chosen as its new headquarters the Mulch Manufacturing 100,000-square-foot building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing, Inc. and National Storm Recovery, LLC, and has ample room to expand as the needed.

Leadership

National Storm’s Sustainable Green Team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

• Tony Raynor, Chief Executive Officer
• Edward Lee, Chief Operating Officer
• Ralph Spencer, Director of Business Development, Strategic Acquisitions
• Steve Ogden, ISA-Certified Arborist
• Rick Starcher, Master Chemist
• Peder K. Davisson, Esq., Corporate/Securities Counsel

For more information, visit the company’s website at www.CentralFloridaArborCare.com/Storm-Recovery

NOTE TO INVESTORS: The latest news and updates relating to NSRI are available in the company’s newsroom at http://ibn.fm/NSRI

• Predictive Oncology subsidiary TumorGenesis developing faster, less costly and more accurate PDx cancer models that better mimic patient’s tumor
• TumorGenesis revolutionary technology will provide pharmaceuticals with quicker, more effective drug development while significantly improving patient outcomes
• POAI to begin sales of TumorGenesis’ innovative culture media in the first half of 2020

TumorGenesis, a flagship subsidiary of Predictive Oncology Inc. (NASDAQ: POAI), has made concrete steps in identifying and separating cancer-related biomarkers, which is likely to speed the development of new and effective therapeutics. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures of ovarian cell types while growing them in the laboratory. This breakthrough approach is likely to help POAI become a frontrunner in providing the needed tools for personalized medicine and new drug development, which carries important implications for the company’s future valuation.

For years, clinicians believed that isolating a patient’s tumor would lead to new understandings about the cancer – this has proven to be only partly true and has resulted in costly, ineffective drug diagnoses that have robbed patients of precious time. To substantially enhance the effectiveness of cancer treatment, a much more diverse picture of patient tumors is needed – one that takes into account each individual’s unique biodiversity and the unique biodiversity of each tumor. POAI’s TumorGenesis division is at the forefront of a whole new trend in cancer research that revolves around patient derived xenografts (PDx).

Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By “fooling the tumor” with an imitative environment, new drugs are able to be tested and potentially approved – all without subjecting cancer patients to aggressive, potentially ineffective drugs. The cancer cells are tricked into thinking they’re still multiplying inside the patient, which makes the tumor behave as it would normally – revealing more precise cancer biomarkers. TumorGenesis’ unique research approach benefits from the parent company’s enormous database of tumor drug response profiles and artificial intelligence-driven predictive modeling capabilities.

TumorGenesis has developed its proprietary methodology using PDx to culture tumor cells in vivo, (i.e. in living organisms). These cell models can be then tested repeatedly for various new drugs to establish personalized therapeutics. This patient-specific data is revolutionizing the way cancer is treated today, and POAI, through its strategic subsidiary arms, poses an attractive option for investors looking to invest in the cancer treatment of tomorrow.

In light of the traditional past practice of studying how cancer cell lines react to induced mutation (a practice that has since proven to be seriously flawed), cancer researchers are shifting their focus to PDx techniques, which have grown into a multibillion-dollar industry. TumorGenesis is poised to become a dominant figure in this emerging space. US Biological Corporation of Salem, Massachusetts has been selected as the distributor of TumorGenesis media and discovery kits.

Parent company POAI already presents a major leap in the cancer research industry. As of today, the company has validated and will begin sales its new PDx models for ovarian cancer (http://ibn.fm/1hsgV) in the first half of this year. The company now has 25 validated ovarian cancer cell types. This signifies remarkable comprehension of the notoriously difficult-to-detect cancer, as 15 out of the 25 cell lines account for nine out of ten ovarian cancers diagnosed worldwide. As researchers separate these types and analyze their reaction to drug samples, POAI’s findings could greatly improve future patient outcomes.

In line with its CancerQuest2020 initiative, ovarian cancer is just POAI’s first target. With monetization, the company plans to diversify and expand its catalogue of validated cancers; future plans include thyroid, breast, colon, and prostate cancers, among others.

TumorGenesis presents POAI with multiple revenue streams. Based on its unique PDx samples, the company is testing drugs individually and holistically against its massive library of ovarian cancer cell types. Using this approach, the company is building kits for cancer research laboratories worldwide. The company is also committed to immunological research. Its proprietary Ovarian Cancer Kit can help simulate a patient’s cancer environment, and these new tools can be used to help isolate various strains of the complex tumor environment that to this date, have never been isolated but seen by genetic and proteomic analysis. Once isolated, these subtypes of tumor cells can be studied, new antibodies developed and new tools researched for killing not just the fast growing tumor variants but also the entire tumor.

The latest developments in TumorGenesis’ PDx efforts could secure a significant segment of the cancer research industry. TumorGenesis’ advances in ovarian cancer models provides POAI a unique competitive advantage that could easily be converted into rapid market expansion. This expansion would not only further validate efficacy and grow market share, it would likely lead to significant increase in POAI’s market valuation. As the company continues achieving milestones of its CancerQuest2020, POAI is setting up to become one of the biotech superstars of 2020 and beyond.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Trxade announces pricing of a firm commitment public offering of 806,452 shares of its common stock
• Proceeds to be used as working capital and to fund future acquisitions
• Company’s B2B online purchasing platform currently has 11,900 pharmacies registered and is registering 100+ New pharmacies per month

Trxade Group Inc. (NASDAQ: MEDS), an integrated drug delivery, procurement, and healthcare platform that offers healthcare buyers and sellers of pharmaceuticals increased profit margins, announced that its common stock has begun trading on the Nasdaq Capital Market under new ticker symbol ‘MEDS’, as of February 13, 2020. The company’s common stock will cease trading on the OTCQB.

The company also announced the pricing of a firm commitment public offering of 806,452 shares of its common stock at $6.50 per share. Trxade Group granted a 45-day option to underwriters to buy up to an additional 120,967 shares of common stock to cover overallotments, or post-reverse stock split. The offering was expected to close on or around February 18 (http://nnw.fm/nfIU9) (http://ibn.fm/keqve).

Before deducting offering expenses and underwriting reductions, Trxade Group expects gross proceeds of $5.2 million from the sale of common stock in the offering. The company intends to use the net proceeds from the offering for general purposes and working capital, as well as to possibly fund acquisitions of other products, companies or technologies.

Dawson James Securities, Inc., Dougherty & Company LLC, and View Trade Securities, Inc. are acting as the underwriters of the offering.

Trxade has developed a proprietary web-based e-commerce platform (S2P – Supplier to Pharmacy) that enables trade among pharmaceutical, accessory, and service buyers and sellers. The platform currently has about 11,500 pharmacies as registered users, through which it reaches between 12 million and 15 million patients. The company aims to reach most, if not all, of the estimated 24,000 independent pharmacies currently operating in the U.S., with combined pharmaceutical purchases of $93 billion per year. The U.S. pharmaceutical industry, which is worth $330 billion, is comprised of 1,500 state-licensed suppliers and more than 65,000 pharmacy facilities, 24,000 of which are independent.

The platform offers multiple benefits such as significant discounts that contribute to a 7-10 percent decrease in the annual purchase expenses for pharmacies; no registration and transaction fees for pharmacies; a simple and intuitive interface that helps pharmacies compare prices and select the best offer with guaranteed security for purchases and payments. Revenue is generated from two primary sources: the growing number of registered users and an increase in the platform’s utilization rate among registered users. The company is adding over 100 pharmacies to its platform per month and has plans to soon provide access to other healthcare providers, such as hospitals, veterinary clinics and long-term care facilities.

The U.S. healthcare market is currently valued around $4 trillion. As the general population ages, further growth is expected, which in turn will have increasing impact on consumers as out-of-pocket expenses rise as well. Trxade aims to lower prescription drug costs by attacking the inefficient value chain, delivering drugs directly to independent pharmacists and consumers, and offering efficient purchasing and price transparency. Its integrated drug procurement, delivery and healthcare platform also delivers increased profit margins.

Founded in 2010, the company is comprised of three synergistic operating platforms: the B2B trading platform with 11,900 registered pharmacies, licensed virtual Wholesale and Mail Order Pharmacy capabilities including the mobile app DelivMeds, as well as the newly acquired assets of Bonum Health, a telemedicine platform.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS http://ibn.fm/MEDS

• Sharing Services Global Corporation offers entrepreneurial opportunities, broad range of products and services for contemporary consumers
• SHRG will be holding the Happiness Revolution Convention 2020 this spring
• Sharing Services Global facilitates Blue Ocean Strategy, symbolic of immense opportunity in the entrepreneurial space

Sharing Services Global Corporation (OTCQB: SHRG) is a holding company that owns, operates or controls an interest in companies specializing in the direct-selling industry. The company’s emphasis is on direct selling, and SHRG has grown by thousands of independent sales representatives over the past year. Through one of its strategic avenues to help empower its growing body of Elepreneurs, the company recently announced its 2020 Happiness Conference, slated to take place April 16-19 in Grapevine, Texas.

Planned and executed by SHRG’s wholly owned subsidiary, Elepreneurs LLC, the Happiness Revolution Convention 2020 is designed specifically to benefit, support and encourage the company’s international network of independent representatives, called Elepreneurs. Elepreneurs LLC provides basic and advanced programs for new and experienced entrepreneurs who are concentrating on their direct-sales careers.

Held at the Gaylord Texan, the conference will feature invaluable networking opportunities, as well as meetings with field leaders and the SHRG home office team. Other conference highlights include the launch of new products, new tools and new apparel for the benefit of Elepreneurs; expert training for Elepreneurs in the areas of skills, social media and leadership; and the opportunity to learn from Ray and Jessica Higdon, creators of hit reality show ‘Play to Win’, where motivated contestants tackle sales and business challenges to win a life-changing opportunity (http://ibn.fm/VIquj). Additionally, The Happiness Revolution Convention 2020 offers an array of teambuilding and networking activities, including a welcome party, a ‘70s party, memorable entertainment, a family room, and a variety of team events.

Sharing Services Global’s dedication to maximizing shareholder value is evident in the operation of its two main subsidiaries: Elepreneurs LLC, a direct-selling company, and Elevacity Global LLC, a products company. SHRG’s focuses on companies that sell directly to the consumer through independent representatives or that offer services ranging from health and wellness, energy, technology, insurance services, training and media.

As SHRG focuses on organic growth, expanding its ever-growing team of independent sales representatives, recent statistics indicate that the direct-selling model is flourishing. The Direct Selling Association (DSA) noted in its 2019 Direct Selling Growth and Outlook Survey (http://ibn.fm/GP2re), which was released in June 2019, that “the number of people selling products or services using the direct selling model grew 1.6 percent, with more than 6 million U.S. entrepreneurs selling in either on a part-time or full-time basis.” The report further noted that “the U.S. direct selling industry is moving in a very positive direction. Retail sales were strong, thanks largely to the U.S. direct sales force and their ability to attract millions and millions of customers.”

Also fueling that growth for Sharing Services Global is its Blue Ocean Strategy, which empowers entrepreneurs. The Blue Ocean Strategy involves elevating home-based entrepreneurs; generating organic growth; and creating successful independent business leaders. These business leaders – SHRG Elepreneurs – promote the Elevacity line of products to customers.

Elevacity Global manufactures and distributes all products that Elepreneurs market. The health and wellness products contain superior, scientifically backed ingredients designed to stimulate specific happiness hormones referred to as D.O.S.E., dopamine, oxytocin, serotonin, and endorphins (http://ibn.fm/TbEZM). With its product line of elevated health and wellness products, Elevacity Global is a promising revenue stream for SHRG.

Sharing Services Global continues to maintain a strong position in the worldwide direct-selling market. Of note to investors is that the company is experiencing rapid growth with its record-breaking increase in sales in 2019 due to its launch of innovative health and wellness products. Sharing Services Global is set to dynamically leverage the forecast growth for the direct-selling industry and continues to work to elevate its Elepreneurs to greater levels of success.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• SRAX CEO discusses company’s milestone achievements in 2019
• Two flagship products – BIGtoken and SRAX IR – are generating multiple recurring revenue streams
• SRAX is strategically positioned for strong 2020 as proprietary products start contributing to the top line
• Company moves from development cycle to revenue cycle, anticipates 2020 growth

In an exclusive interview with NNW’s Stuart Smith, SRAX Inc. (NASDAQ: SRAX) CEO Chris Miglino discusses the company’s milestone achievements in 2019 as well as its ambitious plans for 2020 to harness the brand recognition built on the emerging regulation underpinning consumer data protection (http://ibn.fm/G72dC).

“That was a big year for us in terms of getting our BIGtoken product out to the market and getting new products out to market in general,” Miglino said, summarizing major developments of 2019. “BIGtoken and SRAX IR came to maturity of being able to start generating revenue this year, and we are excited about that going forward. BIGtoken ended up the year with around 16.5 million users on the platform, all of whom signed up within a year.”

SRAX, a digital marketing and consumer data management technology company, is revolutionizing consumer data collection through a secure and transparent platform called BIGtoken. BIGtoken unlocks the data, helping brands reveal their core customers and the characteristics of those customers across different marketing channels, while at the same time allowing consumers to make money from selling the data they create as part of their digital footprint. In addition, the company developed the SRAX IR platform, which helps public companies communicate with existing shareholders and also reach potential investors by leveraging data on their behavior.

Speaking about SRAX IR, Miglino noted that the product is building a valuable community of public stock issuers, with 35 companies joining the platform. SRAX IR helps public companies manage the relationship with their existing and potential investors by leveraging data on stock buyers’ and sellers’ activities to uncover trends in their behavior over time, and by tracking ROI on investor relations programs. Miglino reports that the product is receiving positive feedback from users as it enables them to better communicate with their investor base.

SRAX is currently in an excellent position as BIGtoken is generating multiple revenue streams from market research, customer activation and customer data segments selling to clients such as Proctor & Gamble, Kraft, Sun-Maid and others, said Miglino, who also described ambitious plans for the future: “We have some amazing plans in 2020 about what we’re going to be launching on the platform. 2019 for us was the year to tee up all the platforms and the technology to start generating revenue, and 2020 is where we’re going to start to see both BIGtoken and SRAX IR start to contribute to the top line for the company.”

Miglino pointed out that the year has already started strong as SRAX announced in January that it partnered with Experian to offer financial services to BIGtoken users (http://ibn.fm/tJawt), a deal that Miglino expects to be a big revenue generator both for SRAX and Experian.

Speaking about SRAX’s outlook for 2020, Miglino said that the company established powerful partnerships with both publishers and marketers to bring people on to the BIGtoken platform. As a result, the company expects an increasing number of consumers to join the platform, while SRAX IR anticipates continued growth of recurring revenue streams. “Both platforms are keyed up now to start contributing to the company financially,” said Miglino. “As we move from the development cycle to the revenue cycle, we are very excited about that.”

With the Q3 results released in November 2019 showing that vertical sales increased 17% year on year while net income reached 1.4 million, the financials reflect that SRAX is on the right track towards achieving these plans (http://ibn.fm/jwGAP). As the company continues its strategic growth, SRAX represents an attractive opportunity for investors seeking to capitalize on early entrance into the lucrative consumer-data space.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Nightfood has superior nutritional profile for mothers-to-be
• Award-winning ice cream increasingly recommended to pregnant women by service providers.
• Nightfood aims to leverage untapped pregnancy market of up to 3 million women to accelerate national supermarket rollout

Nightfood Holdings Inc. (OTCQB: NGTF) is changing the conversation around ice cream through its subsidiary Nightfood Inc., creator of an award-winning, nutrient-rich ice cream that is taking the pregnancy community by storm. With its unique and healthier nutritional profile, Nightfood is being recommended to pregnant women by their providers as a better option when pregnancy cravings inevitably hit.

Nightfood is in position to dominate the untapped pregnancy ice cream market, which consists of over 3 million American women at any given time. With over 10,000 new women entering the category every day, company management believes this highly motivated consumer demographic can be an immediate and constant source of new and loyal long-term consumers (http://ibn.fm/A1Ak6). Nightfood CEO Sean Folkson believes Nightfood has an unassailable advantage with this highly desirable consumer segment, stating, “The simple fact is that no other ice cream brand can address the pregnancy market with any integrity, because their formulations and nutritional profiles just don’t align the way Nightfood does.”

Nightfood offers expectant mothers a way to satisfy their biologically driven nighttime cravings while feeling good about what they’re putting into their bodies. Unlike any other brand on the market, Nightfood’s ice cream packs extra calcium, magnesium, zinc, fiber, and protein combined with a lower sugar content—all sought-after characteristics of a prenatal diet.

Formulated by sleep and nutrition experts, Nightfood’s unique ice cream also includes ingredients to fight heartburn and other issues that are particularly important to the needs of pregnant women for high-quality sleep, healthy bone density and nervous system health. With an eye still focused on the broader market, Folkson asserts that the company is not rebranding the product as a “pregnancy” ice cream, stating that “Nightfood remains a mainstream product for over 200 million American men and women,” and that “moms and their families can stick with Nightfood through the years, not just through birth.”

Scientific studies confirm links between pregnancy and ice-cream cravings, with research affirming that these cravings are biologically driven. Since pregnant women have increased nutritional needs required to support their health and growing babies, the cravings may be representative of an increased need for certain micro and macro-nutrients. Dr. Lauren Broch, a Nightfood advisor holding an MS in human nutrition whose practice focuses on women’s health, including pregnancy, remarked, “pregnant women are not going to stop craving and eating ice cream, so let’s help them identify a healthier choice for their needs.”

In addition to landing media coverage on major outlets such as The TODAY Show, the Wall Street Journal, Oprah Magazine, USA Today, the Washington Post and Parents Magazine, Nightfood also engages local efforts to increase brand awareness among expectant mothers by sponsoring events at childbirth education workshops, prenatal exercise studios and other businesses that serve pregnant women.

Nightfood management has pointed out that the velocity with which information spreads within this demographic will allow the Nightfood brand to establish a stronghold very quickly. “From social media groups and blogs to the mainstream media, and local workshops, today’s pregnant women share and consume tremendous amounts of information at lightning fast speeds,” Jessie Trinchard, Nightfood’s sales director, stated in a news release.

With multiple major supermarket chains committed to adding Nightfood in the coming weeks, Nightfood is poised to become the preferred ice cream brand of pregnant women across the country right here in 2020.

Headquartered in Tarrytown, New York, Nightfood is revolutionizing the world of night snacking with its innovative offerings. With an eye on America’s $50 billion nighttime snacking problem, Nightfood is focused on improving the late-night snacking choices of consumers while becoming a national brand with a billion-dollar valuation. With increased brand recognition fostered by the uber-connected pregnancy community, Nightfood indicates significant untapped potential for market penetration.

For more information, visit the company’s website at www.Nightfood.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• SHRG achieves record sales of health and wellness products through direct selling by home-based entrepreneurs
• Expert advisors key to company’s sales success through development of hormone-balancing products that improve mood and sense of well-being
• 2019 record sales continue this year with sales rising each quarter, fueling plans for international expansion

Sharing Services Global Corporation (OTCQB: SHRG), a holding company working through subsidiaries Elepreneurs LLC and Elevacity Global LLC, operates with a strategy of empowering home-based entrepreneurs to sell health and wellness products directly to consumers. The company’s expert leadership supports these individuals, known as Elepreneurs, through training programs that give them the tools needed to achieve business success while elevating the physical and emotional well-being of their customers.

Led by CEO John “JT” Thatch and a team of industry experts in the nutrition, personal development and direct-selling spaces, the company has made the happiness industry a profitable enterprise. According to its 10-Q filed with the SEC (http://ibn.fm/oIYg3), SHRG reported record sales growth in 2019, with sales continuing to grow each quarter (http://ibn.fm/V36EB).

Prior to joining SHRG in March 2018, Thatch had successfully launched, owned and operated several businesses and is an accomplished entrepreneur himself, he has the synergistic ability to support SHRG Elepreneurs through company operations while simultaneously using his knowledge and experience to create shareholder value for the organization.

From human-resource concerns to product creation and direct-sales operations, all aspects of SHRG’s operations are covered by its team of expert advisors across a range of key areas. Leading product development is Kevin Thomas, a 36-year expert in nutritional supplement creation with a robust intellectual-property portfolio.

Direct-sales expertise and training methodology is brought to the company by respected leaders and built around a vision of Shawn Achor, the New York Times best-selling author of The Happiness Advantage and Big Potential, who brings years of experience from working in more than 50 countries and having worked with nearly half of the Fortune 100 companies.

The combined leadership knowledge of SHRG’s management team is reflected in the company’s success, extending forward through each Elepreneur’s personal mission to elevate their customer’s well-being through the sales of the Elevacity product line. Since an individual’s mental and physical well-being is highly dependent on hormone balance, Elevacity addresses these issues through its D.O.S.E. line of products that are based on a unique combination of dopamine, oxytocin, serotonin and endorphins. In addition to these patented supplements, SHRG also offers skin-care products made from natural ingredients for all skin types.

Headquartered out of a 10,000-square-foot facility in Plano, Texas, SHRG has planned for future expansion as the company grows. Customer-service facilities, operations and training rooms, and a video-production suite are currently available onsite with room for growth in each area. In addition, SHRG is looking forward to international expansion. The company’s line of products is currently available in the United States, Canada, New Zealand and Australia.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• CBD Biotech seizing immense opportunities in untapped CBD Chinese market
• CIIX operates both online, physical CBD stores in addition to developing first Chinese, CBD-based social media app
• CIIX’s hemp-based products fully legal in China with plans for further development, Nasdaq IPO this year

ChineseInvestors.com Inc. (OTCQB: CIIX), a leading U.S.-based financial consultancy for Chinese-speaking investors, is positioning its subsidiary, CBD Biotech Inc., as a leader in the Chinese-based CBD market through increased development of legal hemp-based products.

Clinically shown to help with anxiety and stress-related disorders (http://ibn.fm/dbNam), CBD-based products may be helpful for dealing with the coronavirus outbreak, CIIX CEO Warren Wang stated during a recent interview (http://ibn.fm/myK5y). While clarifying that medical help is essential, Wang shared his opinion that CBD products “can help your immune system.” Wang also noted that CBD Biotech Inc. will be “the first one in the public market field inside China selling CBD.”

In partnership with a well-known CBD brand, CIIX currently markets to the massive Chinese-speaking market worldwide through its website ChineseCBDOil.com – one of the world’s first online stores in the Chinese language that provides industrial-hemp-derived, CBD soft gels, capsules and concentrates. In order to support the company’s online efforts, CIIX has developed a Yelp-style mobile app to be used as a platform for Chinese consumers to review and discuss various cannabis products, making it the first marijuana-based social media mobile application for Chinese-speaking customers in the world. In addition to operating online, CIIX also serves the Chinese population of San Gabriel, California, through its retail store.

With few competitors and plenty of room for market dominance, CIIX plans to seize opportunities in the fully legal, hemp-based CBD nutritional and cosmetic product markets in China. While cannabis is still illegal in the country, prohibitory laws do not apply to hemp-based CBD cosmetics. Unaffected by changing regulations, CIIX is able to operate in a stable environment with the freedom to focus investment on the research and development of new CBD products. The company has established a three-year development plan for CBD Biotech in mainland China and has hopes for a Nasdaq IPO in 2020.

With a global Chinese-speaking base that continues to grow, CIIX disseminates investment information through its proprietary financial news media and content platform. The company assists its subscriber base in making informed investment choices through its exclusive service, called the ChineseInvestors Method. This investment strategy integrates personalized advice with web-based tools, empowering Chinese investors to make optimal investment decisions based on their needs and risk profile. All services by the company are offered in both traditional and simplified Chinese-language character sets (http://ibn.fm/NiIwr).

Besides offering its audience of investors real-time market commentary, analysis and educational-related services, the company also provides consulting services to smaller private companies that wish to go public, in addition to advertising, social media, and public relations consulting services.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX